Air pollution
Living in a highly polluted area can be equivalent to smoking 20-30 cigarettes a day, accelerating lung aging and increasing the risk of chronic respiratory diseases, such as COPD. Prolonged exposure to tobacco smoke and air pollutants can lead to irreversible damage, including lung cancer. Dr. Gurmeet Singh Chabbra, Director
Lung diseases
Investigations into ventilator-induced lung injury (VILI) have led to significant concerns in the medical community, particularly in the context of mechanical ventilation. VILI is characterized by inflammatory signaling pathways, leading to lung repair processes that may result in pulmonary fibrosis. Researchers from Shandong University, led by Huan Liu, have published
Lung diseases
Preclinical studies have long sought to understand the therapeutic potential of umbilical cord derived mesenchymal stem cells (UC-MSC) in lung regeneration. Recent research has provided convincing evidence that UC-MSC can prevent lung injury and promote lung regeneration. However, their limited therapeutic efficacy within clinics has been a long-standing concern. Current
Pediatrics
Researchers have been exploring the potential of stem cell therapy for pediatric respiratory diseases, which pose significant morbidity and mortality risks due to their acute and chronic nature. Current treatment approaches focus on symptomatic relief rather than regenerative solutions, leading to calls for innovative therapies. Recent advancements in stem cell
Pediatrics
New research from Murdoch Children's Research Institute in Victoria, Australia, has made significant strides in diagnosing and treating childhood interstitial lung diseases (chILD), which have long been challenging clinicians due to their heterogeneity and poor characterization. Genetic testing has greatly improved diagnosis, and researchers are now focused on
Lung diseases
A U.S. control study conducted between 2010 and 2014 demonstrated vaccine effectiveness (VE) for 1 dose of the thirteen-valent pneumococcal conjugate vaccine (PCV13) against vaccine-type invasive pneumococcal disease (IPD) at 86%. However, the study lacked statistical power to examine VE by number of doses and against individual serotypes. Notably,
